Omnicell (NASDAQ:OMCL) Updates FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL - Get Free Report) updated its FY 2025 earnings guidance on Saturday. The company provided earnings per share (EPS) guidance of 1.000-1.650 for the period, compared to the consensus estimate of 1.770. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion.

Omnicell Stock Up 5.5%

OMCL traded up $1.50 on Thursday, reaching $28.84. 558,700 shares of the company traded hands, compared to its average volume of 560,912. The stock's 50 day moving average price is $31.12 and its 200-day moving average price is $39.10. The company has a market cap of $1.35 billion, a price-to-earnings ratio of 106.83, a PEG ratio of 7.53 and a beta of 0.78. Omnicell has a 52-week low of $22.66 and a 52-week high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.10. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The business had revenue of $269.67 million during the quarter, compared to analyst estimates of $260.18 million. During the same period in the previous year, the company earned $0.03 EPS. The firm's revenue was up 9.5% on a year-over-year basis. On average, sell-side analysts expect that Omnicell will post 1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on OMCL. Wells Fargo & Company raised shares of Omnicell from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $31.00 to $35.00 in a research note on Wednesday, May 14th. Benchmark reduced their price target on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Wall Street Zen raised Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday. Finally, JPMorgan Chase & Co. reduced their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $46.50.

Institutional Trading of Omnicell

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its holdings in shares of Omnicell by 42.1% in the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company's stock worth $627,000 after buying an additional 5,311 shares in the last quarter. Empowered Funds LLC lifted its position in shares of Omnicell by 14.3% during the first quarter. Empowered Funds LLC now owns 9,953 shares of the company's stock worth $348,000 after purchasing an additional 1,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Omnicell by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company's stock worth $4,337,000 after acquiring an additional 4,866 shares during the last quarter. Finally, Jane Street Group LLC increased its position in Omnicell by 201.5% in the first quarter. Jane Street Group LLC now owns 163,664 shares of the company's stock worth $5,722,000 after purchasing an additional 109,382 shares during the period. Institutional investors own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.